Mitochondrial biology is a broad field, not a single treatment category. Elamipretide, often called SS 31 in research discussions, and MOTS c are frequently paired online because both are connected with mitochondria. Their evidence and regulatory histories are substantially different.

Elamipretide now has a specific approved product

FDA granted accelerated approval to Forzinity in September 2025 to improve muscle strength in adults and children with Barth syndrome who meet the labeled weight criterion. The labeling explains that the decision was based on an intermediate clinical endpoint and that continued approval may depend on verification of clinical benefit in confirmatory trials. It does not establish a general anti-aging, fatigue or exercise-performance indication. FDA accelerated approval of Forzinity Forzinity current product labeling

That distinction corrects two opposite errors: calling elamipretide wholly unapproved is outdated, while treating its approval as validation of every retail SS 31 product or wellness claim is also wrong.

MOTS c remains a different research question

The original MOTS c research explored a mitochondrial-derived peptide in cellular and animal models of metabolism. Such work can support a biological hypothesis but cannot establish that administering a retail preparation benefits people. FDA's safety communication highlights the lack of adequate human-exposure information for products containing MOTS c. Original MOTS-c metabolic research FDA safety concerns for certain bulk drug substances

The October 30, 2026 HHS notice concerns a nonbinding draft, conditional section 503A compounding policy. It does not confer FDA approval or establish efficacy, and it does not authorize research-only retail products for human use. October 30 2026 Federal Register notice on draft HHS peptide policy

A meaningful comparison therefore asks what material was tested, in which population and for which endpoint. Shared mitochondrial language cannot establish interchangeability. AXON should treat these as separate evidence histories, with the approved Forzinity indication described precisely and the limits of MOTS c research left visible.